Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110320 | 0.91 | MEN1 (0.49) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL4110505 | 0.86 | P2RY12 (0.49) | P2RY12 | |
| SCHEMBL2419418 | 0.85 | CXCR3 (0.51) | MEN1KMT2ASMN1; SMN2P2RY12 | |
| SCHEMBL31142937 | 0.83 | SMN1; SMN2 (0.68) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL2419355 | 0.81 | P2RY12 (0.62) | MEN1KMT2AP2RY12 | |
| SCHEMBL31050093 | 0.81 | MEN1 (0.52) | MEN1KMT2AP2RY12 | |
| SCHEMBL2417915 | 0.81 | MEN1 (0.52) | MEN1KMT2AHTTSMN1; SMN2P2RY12 | |
| SCHEMBL2419414 | 0.81 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2P2RY12 | |
| SCHEMBL2418785 | 0.81 | MEN1 (0.52) | MEN1KMT2AP2RY12 | |
| SCHEMBL4097482 | 0.81 | P2RY12 (0.63) | MEN1KMT2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | MEN1 2888/4885KMT2A 4642/4885HTT 2552/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | MEN1 2007/4885KMT2A 4406/4885HTT 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.